FDA to reconsider treatment for rare cancer after its surprise rejection

AI Summary

The FDA is reconsidering its position on a treatment for a rare form of cancer after facing backlash regarding its previous rejection. The agency's decision process reflects broader trends in drug approvals for rare diseases.

The rejection of Ebvallo was part of a pattern that suggested top FDA officials had raised the bar for rare disease drugs.